Sun Pharmaceutical Industries Limited

13 total trials 3 currently recruiting 5 completed

Trial Pipeline

RECRUITING Phase 1

Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency

NCT07385547

RECRUITING Phase 2

Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus

NCT07282743

RECRUITING

Safety Study for Prospective Assessment of Pregnancy Outcomes in Patients Treated With Tildrakizumab

NCT03992729

ACTIVE NOT RECRUITING Phase 3

A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.

NCT06611163

ACTIVE NOT RECRUITING Phase 4

A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patients

NCT06425900

ACTIVE NOT RECRUITING Phase 3

Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis

NCT04991116

ACTIVE NOT RECRUITING Phase 3

Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)

NCT04314531

ACTIVE NOT RECRUITING Phase 2

A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis

NCT03997786

COMPLETED Phase 3

Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

NCT04314544

COMPLETED Phase 3

Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis

NCT03897088

COMPLETED Phase 3

A Study to Evaluate the Effect of of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base (Sun Pharmaceuticals Industries Limited)

NCT03528577

COMPLETED Phase 2

Efficacy and Safety Study of SUNPG1623

NCT02980692

COMPLETED Phase 1

Pharmacokinetic and Pharmacodynamic Study of Cyclofem

NCT01699022

What the Pipeline for Sun Pharmaceutical Industries Limited Shows

According to the ClinicalTrials.gov registry, Sun Pharmaceutical Industries Limited is linked to 13 US clinical trials across every stage of research activity. Of those, 3 studies are currently recruiting — about 23% of the sponsor's indexed portfolio — and 5 are already marked complete, representing roughly 38% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

The phase mix for Sun Pharmaceutical Industries Limited reports 7 late-stage studies (Phase 3 and Phase 4 combined) and 5 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

The top therapeutic focus area indexed for Sun Pharmaceutical Industries Limited is Active Psoriatic Arthritis with 3 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial